Dimensional Fund Advisors LP Acquires 68,200 Shares of Takeda Pharmaceutical Company Limited (NYSE:TAK)

Dimensional Fund Advisors LP grew its holdings in Takeda Pharmaceutical Company Limited (NYSE:TAK) by 60.0% in the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 181,929 shares of the company’s stock after buying an additional 68,200 shares during the quarter. Dimensional Fund Advisors LP’s holdings in Takeda Pharmaceutical were worth $2,409,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of the business. Farther Finance Advisors LLC raised its holdings in shares of Takeda Pharmaceutical by 123.6% during the fourth quarter. Farther Finance Advisors LLC now owns 3,575 shares of the company’s stock valued at $47,000 after acquiring an additional 1,976 shares in the last quarter. Crowley Wealth Management Inc. purchased a new position in Takeda Pharmaceutical during the 4th quarter valued at $52,000. Cromwell Holdings LLC bought a new position in Takeda Pharmaceutical in the 4th quarter worth $61,000. Venturi Wealth Management LLC lifted its position in shares of Takeda Pharmaceutical by 554.7% in the 4th quarter. Venturi Wealth Management LLC now owns 5,028 shares of the company’s stock worth $67,000 after purchasing an additional 4,260 shares during the period. Finally, Lindbrook Capital LLC boosted its stake in shares of Takeda Pharmaceutical by 65.0% during the 4th quarter. Lindbrook Capital LLC now owns 5,151 shares of the company’s stock valued at $68,000 after purchasing an additional 2,029 shares in the last quarter. Hedge funds and other institutional investors own 9.17% of the company’s stock.

Takeda Pharmaceutical Trading Down 0.2%

NYSE TAK opened at $13.69 on Thursday. The stock’s 50 day moving average is $14.80 and its 200 day moving average is $14.00. The company has a quick ratio of 0.72, a current ratio of 1.31 and a debt-to-equity ratio of 0.63. The firm has a market capitalization of $43.56 billion, a PE ratio of 34.23, a P/E/G ratio of 0.24 and a beta of 0.26. Takeda Pharmaceutical Company Limited has a twelve month low of $12.58 and a twelve month high of $15.43.

Takeda Pharmaceutical (NYSE:TAK) last released its earnings results on Thursday, May 8th. The company reported $0.16 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.24 by ($0.08). The business had revenue of $7.34 billion for the quarter, compared to analysts’ expectations of $8.02 billion. Takeda Pharmaceutical had a net margin of 4.53% and a return on equity of 9.39%. Research analysts forecast that Takeda Pharmaceutical Company Limited will post 1.64 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Morgan Stanley upgraded shares of Takeda Pharmaceutical from an “equal weight” rating to an “overweight” rating in a report on Wednesday, April 2nd.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.